Alkeon Capital Management LLC Trims Position in BioCryst Pharmaceuticals, Inc. $BCRX

Alkeon Capital Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,464,021 shares of the biotechnology company’s stock after selling 250,000 shares during the quarter. Alkeon Capital Management LLC owned approximately 2.60% of BioCryst Pharmaceuticals worth $41,472,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of BioCryst Pharmaceuticals by 7.7% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company’s stock worth $161,000 after buying an additional 1,288 shares during the last quarter. Royal Bank of Canada raised its position in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 1,458 shares during the period. Captrust Financial Advisors raised its position in BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 1,527 shares during the period. Main Management ETF Advisors LLC boosted its stake in shares of BioCryst Pharmaceuticals by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company’s stock worth $1,005,000 after acquiring an additional 1,824 shares during the last quarter. Finally, Creative Planning boosted its stake in shares of BioCryst Pharmaceuticals by 2.6% during the 3rd quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock worth $672,000 after acquiring an additional 2,280 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $8.22 on Friday. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 6.85 and a beta of 0.74. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.31. The stock’s 50 day simple moving average is $7.31 and its two-hundred day simple moving average is $7.40.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The firm had revenue of $163.28 million during the quarter, compared to the consensus estimate of $151.32 million. During the same period in the prior year, the company earned ($0.13) EPS. The company’s quarterly revenue was up 209.1% compared to the same quarter last year. As a group, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 21,773 shares of the stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.65, for a total transaction of $166,563.45. Following the completion of the transaction, the insider owned 398,751 shares in the company, valued at $3,050,445.15. This trade represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BCRX. Evercore initiated coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 target price on the stock. HC Wainwright boosted their price target on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 15th. Royal Bank Of Canada reduced their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Finally, Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday, March 4th. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.64.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.